Carbamylmethycholine chloride (bethanechol chloride), veterinary-grade active pharmaceutical ingredient, is supplied under model identifier BC-VET-API-102 as a white or almost white crystalline powder intended for incorporation into tablets, injections, capsules, powders, granules, feed premixes, and oral solutions. The compendial assay range is 98.0% to 102.0% on the dried basis. The molecule is a quaternary ammonium carbamate ester with a β-methyl substitution on the choline backbone, giving it greater resistance to acetylcholinesterase-mediated hydrolysis than acetylcholine while retaining muscarinic receptor agonist activity. Because the quaternary ammonium centre remains ionized across intestinal pH, passive membrane permeability is limited, and oral absorption is dependent on cholinergic target tissue access. The API is manufactured under ICH Q7-based good manufacturing practice for active pharmaceutical ingredients and is released with documentation appropriate for veterinary dosage-form manufacturing.

What separates bethanechol chloride from carbachol and pilocarpine in veterinary parasympathomimetic therapy?

Bethanechol chloride differs from carbachol principally by the β-methyl group on the 2-hydroxypropyl chain. Carbachol retains both muscarinic and nicotinic activity, while bethanechol is predominantly muscarinic at therapeutic concentrations. Compared with acetylcholine chloride, which is hydrolyzed rapidly by acetylcholinesterase and plasma cholinesterase, bethanechol is sufficiently stable for oral and injectable administration. Pilocarpine is a tertiary amine alkaloid with greater central nervous system penetration potential; bethanechol is a quaternary ammonium compound and crosses the blood–brain barrier poorly in most species. Neostigmine and other cholinesterase inhibitors act indirectly by increasing acetylcholine at all cholinergic junctions, rather than providing receptor-selective stimulation. Methacholine chloride is another β-methyl-substituted choline ester but is more susceptible to cholinesterase hydrolysis than the carbamate structure of bethanechol. The chloride salt also provides high water solubility, which is technically relevant for aqueous injection and wet granulation, while lipophilic solubility is low.

Veterinary use of bethanechol chloride includes bladder atony, postoperative urinary retention, and non-obstructive gastrointestinal stasis where muscarinic stimulation is indicated. The API is not a finished dosage form and is supplied to licensed manufacturers for formulation, not for direct administration. Published receptor-selectivity data for carbachol and bethanechol chloride in every target species are limited; species-specific pharmacodynamic assessment should be obtained from approved veterinary formulations.

Compendial and manufacturer release parameters for BC-VET-API-102 are applied to each lot. Analytical methods include infrared absorption for identity, non-aqueous titration or ion-pair high-performance liquid chromatography for assay, and loss on drying by USP <731>. Residual solvents are controlled against VICH GL18 with class 2 and class 3 limits appropriate to the synthesis route. For injectable-grade material, the same chemical limits apply, but particle size and bioburden or endotoxin controls are tightened according to the selected aseptic filtration or terminal sterilization process.

The direct compression grade with D90 ≤150 µm is selected for low-dose tablet and capsule blending in canine and feline formulations. The injection and solution grade with D90 ≤25 µm is produced by jet milling or equivalent size reduction and is controlled for bioburden before downstream aseptic processing.

Processing boundary for tablet and capsule manufacture when residual moisture exceeds 0.5%

When residual moisture exceeds 0.5%, bethanechol chloride exhibits measurable hygroscopic behaviour that can compromise powder flow, die filling, and compact ejection. Processing rooms maintained below 40% relative humidity at 20–25°C reduce surface moisture uptake during weighing, blending, and compression. Material intended for direct compression is pre-dried at 60 ± 5°C until loss on drying by USP <731> is ≤0.5%. Above this threshold, upper-punch sticking, picking, and variable tablet weight increase, while hydrolytic cleavage of the carbamate moiety may produce choline chloride and related carbamate degradation products. These degradation products are monitored as related substances in the release specification.

Veterinary tablet formulations typically use microcrystalline cellulose as diluent, croscarmellose sodium or sodium starch glycolate as disintegrant, and colloidal silicon dioxide as glidant. Magnesium stearate addition should not exceed 0.5 wt% in a low-dose direct compression blend because overlubrication reduces compact tensile strength and delays dissolution. Sodium stearyl fumarate at 0.5–1.0 wt% may be substituted where magnesium stearate is undesirable. Hardness is monitored to maintain friability ≤0.8% after 100 rotations under USP <1216>, and content uniformity is evaluated by USP <905> for low-dose tablets where drug loading is below 25 mg or 5% of tablet weight. Dissolution testing by USP <711> should use an aqueous medium at pH 5.5–6.0 rather than high-pH media to avoid artificial hydrolytic degradation during the test.

Capsule filling with hard gelatin shells is feasible only when relative humidity is controlled below 40%; at higher humidity, shell embrittlement and powder cohesion reduce plug uniformity. Hydroxypropyl methylcellulose capsules may be used if moisture exposure cannot be avoided, but dissolution specifications may require revalidation. Hopper discharge with excessive vibration should be avoided because particle size differences between API and carrier can promote segregation. Published data for this exact veterinary-grade material in all capsule filling machines is limited; process qualification is required for each equipment train.

Injectable solution stability boundaries and terminal sterilization constraints

In injectable solution processing, bethanechol chloride is freely soluble in water; a 1% w/v aqueous solution prepared from compendial-grade material has a pH of 5.5–6.5. The carbamate ester is subject to hydroxide-ion-catalyzed hydrolysis, so formulation pH should be maintained between 5.0 and 6.0 for long-term stability. Citrate or acetate buffers at 10–50 mM provide pH control without introducing divalent metal cations that may promote degradation. Phosphate buffers above pH 7.0, carbonate buffers, and borate buffers are incompatible with the carbamate ester because they shift the solution into the hydrolysis-prone range.

Terminal steam sterilization at 121°C for 15 min may be considered only when formulation-specific stability data demonstrate assay retention above 95.0% and total related substances within the release limit. If such data are unavailable, aseptic filtration through a 0.22 µm polyethersulfone or polyvinylidene fluoride membrane is the appropriate processing route. Filter integrity should be confirmed before and after filtration by bubble point or diffusion test according to the filter manufacturer. Sterility is confirmed by USP <71>, and bacterial endotoxins are controlled by USP <85>. The endotoxin limit is calculated as K/M from the labeled veterinary dose; no universal numeric limit applies across all species and injection volumes. Particulate matter for injectable solutions is controlled by USP <788> or the applicable small-volume parenteral method.

Accelerated stability studies for aqueous formulations should include pH, assay, related substances, visible particulates, and sterility at 25°C / 60% RH and 40°C / 75% RH according to VICH GL3 and VICH GL4. Autoclaved material must be re-tested for hydrolysis products before batch release because carbamate degradation may not be visible by visual inspection alone.

When preparing oral powders, granules, and feed premixes, what controls prevent content uniformity loss?

For oral powders, granules, and feed premixes, geometric dilution is the first processing step to prevent content uniformity loss. The direct compression grade with D90 ≤150 µm is generally acceptable, but segregation can occur in high-speed paddle mixers when carrier bulk density differs from the API by more than 0.2 g/cm³. Milled lactose monohydrate, cornstarch, or microcrystalline cellulose are used as carriers; their moisture content should be ≤5.0% to reduce wetting and hydrolytic degradation. Blend uniformity is assessed by sampling at not fewer than 10 positions after a defined mixing time and analyzing bethanechol chloride content. Acceptance values should align with USP <905> or the equivalent statistical content uniformity test for the finished dosage form; for feed premixes, regulatory guidance may permit wider variability only when final feed mixing validation demonstrates consistent distribution.

Wet granulation with water at bed temperatures above 40°C may increase carbamate hydrolysis. Dry granulation, roller compaction, or low-temperature aqueous granulation with immediate drying is preferred. If wet granulation is unavoidable, the granulation liquid should be adjusted to pH 5.0–6.0 and drying completed rapidly at an inlet temperature not exceeding 60°C until loss on drying is ≤0.5%. Alkaline feed carriers, including some dicalcium phosphate grades with suspension pH above 7.5, are not recommended because storage degradation may occur in the final premix. The finished premix should be protected from moisture with heat-sealed foil laminate or equivalent barrier packaging. Published stability data for bethanechol chloride in every specific feed matrix is limited; matrix-specific storage stability studies are required before assigning a shelf life.

Quality system and compendial alignment for veterinary-grade API release

Under the quality system applicable to veterinary active ingredients, the API manufacturing facility operates under ICH Q7-based GMP, with finished dosage-form manufacturing conducted under 21 CFR 210/211 or equivalent national veterinary GMP. Residual solvent control is aligned with VICH GL18, stability testing follows VICH GL3 and VICH GL4, and impurity qualification follows VICH GL11. Analytical method validation should meet ICH Q2(R1) or equivalent. The release documentation for each lot includes the test results from the specification table, a signed certificate of analysis, and a batch record confirming that processing aids do not introduce elemental impurities above recognized limits. Elemental impurities are managed according to ICH Q3D as applied to veterinary products.

Handling boundary: the chloride salt is corrosive to steel surfaces if moist. Product-contact equipment should be 316L stainless steel with electropolished surfaces, and cleaning validation should confirm removal of the quaternary ammonium compound by HPLC rinse analysis. Avoid contact with strong oxidizing agents and strongly alkaline cleaning solutions because hydrolysis and byproduct formation may occur. The API should be stored in tightly closed, low-moisture-permeability containers at controlled room temperature, and opened containers should be reclosed immediately after dispensing.